GTG

GTG and ‘Wellworks for You’ sign B2B sales & marketing deal covering 750 employer groups and 2 million U.S. employees

Retrieved on: 
星期一, 五月 6, 2024
Organization, GTG, Health, ASX, Partnership, Workplace, Risk management, Risk assessment

Executing GTG's inaugural Business to Business (B2B) collaboration with U.S. based Wellworks facilitates the company’s entry into Wellworks' expansive network of self-insured employers with the geneType Risk Assessment Test portfolio.

Key Points: 
  • Executing GTG's inaugural Business to Business (B2B) collaboration with U.S. based Wellworks facilitates the company’s entry into Wellworks' expansive network of self-insured employers with the geneType Risk Assessment Test portfolio.
  • The partnership will provide access to Wellworks’ 750 employer groups and includes more than 2,000,000 covered lives.
  • Wellworks will refer their clients, employer groups and their employees, to geneType for Risk Assessment Testing as part of their overall corporate wellness program.
  • The company has more than 750 employer groups covering more than 2,000,000 lives.

Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering

Retrieved on: 
星期一, 四月 22, 2024
Sale, Prospectus, Ovarian cancer, Warrant, GTG, Regulation D, Health, 3rd Floor, ASX, Research, Genetic testing, Form, ADS, American depositary receipt, B2B, Security (finance)

MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announces the closing of its previously announced registered offering for the purchase and sale of 1,000,000 American Depositary Shares (“ADSs”) (or ADS equivalents in lieu thereof), each representing thirty (30) ordinary shares of the Company, at an offering price of US$2.00 per ADS.

Key Points: 
  • The gross proceeds to the Company from this offering were approximately US$2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering of the ADSs (or ADS equivalents) in the registered direct offering were made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering were filed with the SEC.
  • Authorised for release by the Board of Directors of Genetic Technologies Limited.

Genetic Technologies Announces $2 Million Registered Direct Offering

Retrieved on: 
星期四, 四月 18, 2024
Sale, Prospectus, Ovarian cancer, Warrant, GTG, Regulation D, Health, 3rd Floor, ASX, Research, Genetic testing, Form, ADS, American depositary receipt, B2B, Security (finance)

The closing of the offering is expected to occur on or about April 22, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about April 22, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from this offering are expected to be approximately $2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering of the ADSs (or ADS equivalents) in the registered direct offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC.

New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes

Retrieved on: 
星期三, 四月 17, 2024
USD, Brain, University, Cancer, Genomics, Mutation, GTG, Methylation, Health, Survival, Breast, DNA methylation, ASX, DNA, Patient, GVR, Lung, Disease, Melanoma, Neoplasm, Liquid biopsy, Medical imaging

Huge market opportunity for this advanced portfolio of methylation, mutation and liquid biopsy tests.

Key Points: 
  • Huge market opportunity for this advanced portfolio of methylation, mutation and liquid biopsy tests.
  • Earlier detection of a range of cancers leads to significantly improved patient outcomes.
  • This will significantly drive uptake by making genomic tests widely available and financially accessible to eligible patients.
  • This portfolio of new genomic tests will dramatically change the landscape of oncology diagnostics and help achieve better treatment outcomes for patients.

GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year

Retrieved on: 
星期二, 四月 16, 2024
Education, Breast cancer, Patient, Cancer, GTG, Global Reach, Comfort, Mammography, Risk, Woman, Breast MRI, Health, ASX, Research, Genetic testing, Growth, Disease, General practice, Gynaecology, Pharmaceutical industry

The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.

Key Points: 
  • The geneType team has achieved clinical proof of concept in key markets including general practice, oncology, and gynecology with repeat sales in each of these markets.
  • Clinicians embracing and offering geneType to patients have tended to be:
    Focussed on offering patients the best available care; and
    Comfortable with explaining results to patients.
  • Clinical adoption of geneType is now in more than 12 US States, Canada and nationally in Australia.
  • “Our success in expanding clinician adoption and growth in sales reflects the growing recognition of the transformative potential of personalized medicine,” remarked Simon Morriss, CEO of GENE.

GTG to pilot GeneType in Breast Screen centers across the U.S.

Retrieved on: 
星期四, 四月 11, 2024
Breast cancer, Breast, GTG, Risk, Woman, Montefiore Medical Center, Health, Radar, Florida International University, Communication, ASX, FACS, Patient, Medicine, Breast cancer screening, Risk assessment, Mount Sinai Medical Center, FACOG, Medical imaging

The initiative will pilot the integration of the geneType into breast imaging centers, assisting in the streamlining of care that is currently somewhat fragmented.

Key Points: 
  • The initiative will pilot the integration of the geneType into breast imaging centers, assisting in the streamlining of care that is currently somewhat fragmented.
  • Risk-stratified Decision-Making: By integrating the geneType Breast Cancer Risk Assessment Test into breast imaging centers, patients at higher risk of breast cancer can be easily identified during imaging appointments.
  • Implementation of GeneType: Collaborating with leading breast imaging centers will provide an excellent opportunity for integrating geneType in a high throughput clinical scenario.
  • Its integration into breast imaging centers marks a significant shift in how breast cancer risk is evaluated.

LG ANNOUNCES NEW ADDITIONS TO MONITOR LINEUP IN CANADA

Retrieved on: 
星期三, 四月 17, 2024
AirPlay, Internet, VESA, IPS, Google Calendar, LG, OLED, Microsoft, GTG, FHD, Music, Athlete, CES, WebOS, Stunning, Television

Introduced at CES 2024, 2024 UltraGear™ OLED models and the all-new line up of LG MyView Smart Monitors are now available in Canada.

Key Points: 
  • Introduced at CES 2024, 2024 UltraGear™ OLED models and the all-new line up of LG MyView Smart Monitors are now available in Canada.
  • The new 2024 LG UltraGear™ OLED gaming monitors lineup is designed with gamers and e-sports athletes in mind.
  • Delivering on visual and audio performance and elevating the gaming experience with gamer-centric designs, the 2024 LG UltraGear™ OLED lineup includes the CES Innovation Award-winning 32-inch 4K model (32GS95UE), which is the first LG UltraGear™ monitor to be equipped with the new Dual resolution Mode feature.
  • The latest additions to the LG UltraGear™ OLED lineup and the addition of the all-in-one LG MyView Smart Monitors are a testament to that commitment and further LG's longstanding legacy of OLED leadership and innovation in the monitors category.

EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk”

Retrieved on: 
星期一, 四月 8, 2024
Community, Genomics, Health, Genetic testing, GTG, Partnership, Knowledge, ASX, Security (finance), Risk, Krystal Barter, Woman, Risk assessment, Heart, Movement, BRCA1, Writing, Nursing

"Know Your Risk" is a movement towards empowering every woman with the knowledge to take charge of her health.

Key Points: 
  • "Know Your Risk" is a movement towards empowering every woman with the knowledge to take charge of her health.
  • Community Support: Be part of the launch of a "Know Your Risk" campaign, fostering a supportive community focused on empowering women to make informed decisions about their health.
  • Together with Humanise Health, a leading patient advocacy agency, we are at the forefront of advocating for preventative health and personalized health strategies.
  • This partnership for the "Know Your Risk" event underscores our collective dedication to empowering women with the knowledge to proactively manage their health.

Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market

Retrieved on: 
星期二, 四月 2, 2024
Health, Coronary artery disease, Digital, GTG, Risk, Atrial fibrillation, Patient, Social media, ASX, Risk assessment, Breast cancer, Type

Digital strategies, such as GTG’s approach, are leveraging the growing awareness of the importance and utility of understanding a person’s individual risk of developing a range of diseases.

Key Points: 
  • Digital strategies, such as GTG’s approach, are leveraging the growing awareness of the importance and utility of understanding a person’s individual risk of developing a range of diseases.
  • Know your risk and you and your doctor can take steps to diagnose disease early significantly improving health outcomes.
  • GTG predicts a significant surge in the adoption of risk assessment tests, driven by both patients and doctors.
  • The company sees its geneType digital strategy as spearheading a transformative shift from "sickcare" to genuine "healthcare".

GTG Global Collaborations and Innovation Update

Retrieved on: 
星期二, 三月 26, 2024
Breast cancer, Health, General practice, Professor, BRCA, Public, Public health, Disease, GTG, Risk, Patient, PRS, Research, ASX, Breast, Mammography, University, Royal Melbourne Hospital, Trial of the century, WHI, Risk assessment, Sonneborn–Berger score, Council, Biobank, Publication, Clinical trial, Cancer, CLIA, Medical research, Colorectal cancer, University of Melbourne, Government, UK Biobank, Pharmaceutical industry

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

Key Points: 
  • MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.
  • GTG is one of the co-co-principal investigators of this trial led by Professor Jon Emery.
  • GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care.
  • Leveraging this approach GTG is expanding the portfolio with the following new tests:
    Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS.